Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Consider Using This Risk Tool to Predict T2D Risk

Diabetes Care; ePub 2017 Dec 1; Bergmark, Bhatt, et al

The expanded TIMI Risk Score for Secondary Prevention can practically and reliably predict type 2 diabetes risk, researchers concluded after conducting a study involving nearly 16,500 individuals. Investigators used the tool to compare cardiovascular (CV) event rates in participants from the SAVOR-TIMI 53 trial who had type 2 diabetes and high CV risk/established CV disease. They also tested calibration in the REACH Registry diabetes cohort. Among the results:

  • The expanded TIMI Risk Score predicted 2-year event rates for the composite of CV death, myocardial infarction (MI), and ischemic stroke as follows: ~1% in the lowest- and ~20% in the highest-risk groups.
  • Clear risk gradient was also seen in coronary artery disease (CAD), CAD with or without prior MI, peripheral artery disease, and prior stroke.
  • There was close calibration with REACH Registry cohort.

Citation:

Bergmark B, Bhatt D, Braunwald E, et al. Risk assessment in patients with diabetes with the TIMI risk score for atherothrombotic disease. [Published online ahead of print December 1, 2017]. Diabetes Care. doi:10.2337/dc17-1736.

This Week's Must Reads

Cochrane on Clinician-Focused Weight Loss Tactics, Cochrane; 2017 Nov 30; Flodgren, et al

Cochrane on Delaying Diabetes in People with IGT, Cochrane; 2017 Dec 5; Hemmingsen, et al

Consider Using This Risk Tool to Predict T2D Risk, Diabetes Care; ePub 2017 Dec 1; Bergmark, Bhatt, et al

Dysglycemia Cause in Overweight Adults, Teens, Diabetes Care; ePub 2017 Nov 28; Chen, et al

FDA Approves Semaglutide for Type 2 Diabetes, Novo Nordisk news release; 2017 Dec 5

Must Reads in Diabetes

Cochrane on Delaying Diabetes in People with IGT, Cochrane; 2017 Dec 5; Hemmingsen, et al

Consider Using This Risk Tool to Predict T2D Risk, Diabetes Care; ePub 2017 Dec 1; Bergmark, Bhatt, et al

Dysglycemia Cause in Overweight Adults, Teens, Diabetes Care; ePub 2017 Nov 28; Chen, et al

FDA Approves Semaglutide for Type 2 Diabetes, Novo Nordisk news release; 2017 Dec 5

Hospitalization in Those With, Without Diabetes, Diabetes Care; ePub 2017 Nov 17; Burrows, et al